| Document |
Document Title |
|
WO/2019/009317A1 |
Provided are: a novel compound usable as an organic tag which has a high stability under acidic conditions in peptide synthesis, etc.; and a method for highly efficiently producing a peptide wherein the compound is used as an organic tag.
|
|
WO/2019/008025A1 |
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...
|
|
WO/2019/008595A1 |
The present invention relates to an efficient process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and pharmaceutically acceptable salts thereof involving use of novel intermediates.
|
|
WO/2019/002571A1 |
This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prev...
|
|
WO/2019/002344A1 |
The invention discloses a method for preparation of alpha-methyl-L-proline starting from proline and comprising three steps, first a conversion with chloral, then a conversion with methyl bromide and then a conversion with aqueous HCl.
|
|
WO/2019/003573A1 |
The present invention provides a compound represented by formula (1) (in formula (1), R1 and R2 each independently represent a group represented by formula (2) or NHR0 (where R1 and R2 are not simultaneously NHR0), R0 represents any one ...
|
|
WO/2018/235966A1 |
The present invention provides a compound which has an excellent inhibitory activity on histone acetyltransferase of EP300 and/or CREBBP, or a pharmacologically acceptable salt of the compound. A compound represented by formula (1) or a ...
|
|
WO/2017/191000A9 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2018/140435A9 |
The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
|
|
WO/2018/236153A1 |
The present invention relates to a.method for preparing intermediates of 4- methoxypyrrole derivatives. The preparation method according to the present invention has advantages that the production cost can be lowered by using inexpensive...
|
|
WO/2018/231843A1 |
A compound according to Formula (I):, wherein Z is: (II).
|
|
WO/2018/232005A2 |
The present disclosure provides compounds and nanostructures having one or more quaternary ammonium salts, compositions including the compounds and nanostructures, and methods useful for treating conditions using the compounds, nanostruc...
|
|
WO/2018/232120A1 |
The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanop...
|
|
WO/2018/230329A1 |
The present invention addresses the problem of providing an oral pharmaceutical composition that (1) has reduced bitterness of levetiracetam of which a single dose is a large amount, (2) provides good ingestion feeling, and/or (3) has a ...
|
|
WO/2018/227067A1 |
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...
|
|
WO/2018/227023A1 |
Various compositions are disclosed. The compositions of composition-immune stimulatory compound conjugates are also provided. Additionally provided are the methods of preparation and uses of the composition-immune stimulatory compound co...
|
|
WO/2018/226976A1 |
The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers,...
|
|
WO/2018/222647A1 |
This disclosure relates, in part, to compounds of Formula (1) (including all stereoisomers), N-oxides of such compounds, and salts of such compounds and N-oxides: wherein wherein L, Y1, R1, J, Q1, R7, Y2, R9 and Q2 are as defined in the ...
|
|
WO/2018/220646A1 |
The present invention relates to an improved process for the preparation of (2S)-2- [(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl] butanamide compound of formula- 1, its intermediates, novel salt compounds of intermediates of the compoun...
|
|
WO/2018/218281A1 |
A process for inhibiting the formation of gas hydrates in a hydrocarbon fluid comprising adding to the hydrocarbon fluid, a gas hydrate anti-agglomerate which is a biodegradable anti-agglomerant derived from a naturally occurring substance.
|
|
WO/2018/221971A1 |
The present invention relates to a method for preparing intermediates of 4-methoxypyrrole derivatives. The preparation method according to the present invention has advantages that a high-temperature reaction is not required as a whole, ...
|
|
WO/2018/220355A1 |
The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquiti...
|
|
WO/2018/219309A1 |
The present invention relates to a vinylarene derivative which modulates or inhibits the enzymatic activity of indoleamine 2,3-dioxygenase 1 (IDO-1), and the use thereof, and further relates to a vinylarene derivative and the use thereof...
|
|
WO/2018/222646A1 |
Disclosed are compounds of Formula (1), including all stereoisomers, N-oxides, and salts thereof wherein W, R1, J, Q1, R7, R8, Y, R9 and are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formul...
|
|
WO/2018/215818A1 |
The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and...
|
|
WO/2018/216800A1 |
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...
|
|
WO/2018/215799A1 |
The present invention relates to compounds of Formula (I) that function as inhibitors of bacterial metallo-beta-lactamases. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical composi...
|
|
WO/2018/209616A1 |
Provided are an α-amino acrylate microbicide, and a preparation method therefor and uses thereof. Based on the principle of pesticide molecular design, the structural reform of the agricultural anti-plant virus activity is carried on le...
|
|
WO/2018/213150A1 |
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...
|
|
WO/2018/213813A2 |
The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination...
|
|
WO/2018/211080A1 |
The disclosure provides a salt of Formula IIb, a process for manufacturing thereof, and uses thereof. (Formula IIb)
|
|
WO/2018/213686A1 |
The present invention is directed to novel crystalline forms of 5-(4-{[(2- fluorophenyl)methyl]oxy}phenyl)-prolinamide hydrochloride, to the use of said crystalline forms in treating diseases and conditions mediated by modulation of volt...
|
|
WO/2018/206878A1 |
The invention relates to a method for the synthesis of N-acyl proline or N-acyl 3-hydroxy proline by means of the amide formation of a fatty acid at a high temperature, an intermediate composition of the method, and a cosmetic compositio...
|
|
WO/2018/209290A1 |
A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carb
oxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carb
oxamide using selective crystallization with chir...
|
|
WO/2018/199040A1 |
By performing ion exchange column chromatography on an aqueous solution containing a compound A represented by formula (A) and citric acid or by treating the aqueous solution with calcium carbonate, the citric acid in the aqueous solutio...
|
|
WO/2018/199146A1 |
Provided is a novel method for producing amide compounds at high stereochemical selectivity. This method for producing amide compounds is provided with an amidation step for reacting an aminoester compound represented by general formula ...
|
|
WO/2018/197714A1 |
The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof. The compounds are useful in the treatment of cancers.
|
|
WO/2018/193385A1 |
The present invention relates to 4-substituted phenylamidine derivatives of the general formula (I), wherein R5-R6, ArA4, D, G, B, Q and an integer m have the meanings as defined in the description. The invention further relates to metho...
|
|
WO/2018/195439A2 |
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.
|
|
WO/2018/191789A1 |
The invention relates to compounds of Formula (I) and methods for their preparation. Also described are pharmaceutical compositions comprising a compound of Formula (I) and their use in the treatment or prevention of conditions associate...
|
|
WO/2018/189157A1 |
Methods are disclosed for converting a carboxylic acid by using a diboron reagent to convert the carboxylic acid or imide ester derivative of a carboxylic acid to a boronic ester. The method may involve providing an imide ester, such as ...
|
|
WO/2018/189214A1 |
The present invention relates to a method for binding to a target molecule comprising an aldehyde a compound derived from N- (2-aminoethyl)pyrrole, which compound also comprises a moiety of interest, to compounds (conjugates) obtained by...
|
|
WO/2018/189546A1 |
The present invention relates to chemical linkers and protecting groups, compounds and compositions containing the chemical linkers or protecting groups, and intermediates and processes that can be used to prepare them. The chemical link...
|
|
WO/2018/188356A1 |
Provided are a crystalline form of spirotetramat of formula (I), a crystal preparation process, the analyses of the crystal through various analytical methods and using the crystalline form to prepare a stable agrochemical formulation. T...
|
|
WO/2018/186040A1 |
Provided is an ionic liquid, characterized in containing a cationic component and an anionic component, and in that the cationic component comprises a group having a perfluoropolyether chain and a group having a hydroxyl group.
|
|
WO/2018/184890A1 |
Described are substituted pyrrolidinones of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the gr...
|
|
WO/2018/187411A1 |
Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an ac...
|
|
WO/2018/183538A1 |
Disclosed herein, inter alia, are nucleotide analogues, and methods of use thereof, having cleavable orthogonal linkers.
|
|
WO/2018/177837A1 |
The invention relates to 4-cyclopentyl- and 4-cyclopropyl-2-oxopyrrolidine-3-carboxamide derivatives and related compounds of general formula (I) as herbicidal plant protection agents, in particular for controlling weeds and/or weed gras...
|
|
WO/2018/178397A1 |
The invention relates to the synthesis of amphiphilic amino acid derivatives, in particular to a method for the N-alkylation of an unprotected amino acid or the N-terminus of an oligopeptide substrate, comprising reacting said unprotecte...
|
